Kestra Medical Technologies (KMTS) Q1 2027 Financial Results Summary
QuoteReporter
Kestra Medical Technologies (KMTS) Q1 2027: Revenue Soars 60% YoY — Strong Growth Momentum
Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) reported impressive financial results for the first quarter of fiscal year 2027, ending July 31, 2026. The company generated revenue of $31.0 million, marking a significant increase of $11.6 million or 60% compared to the prior year period, when revenue was $19.4 million. This robust growth underscores the company's strong market position and effective execution of its strategic initiatives.
Analyst View
This quarter is a positive outcome for shareholders, reflecting Kestra's ability to capitalize on market opportunities and expand its product offerings. The substantial revenue growth, coupled with an increase in gross margin to 56.5% from 45.7% in the prior year, indicates that the company is not only growing but also improving its profitability profile. However, the increase in operating expenses and net loss should be monitored closely as they could impact future profitability.
Key Financial Metrics
- Total Revenue: $31.0 million, up 60% YoY from $19.4 million
- Gross Profit: $17.5 million, compared to $8.9 million in the prior year
- Gross Margin: 56.5%, up from 45.7% YoY
- GAAP Operating Expenses: $55.2 million, compared to $37.7 million in the prior year
- GAAP Net Loss: $44.1 million, compared to a net loss of $25.8 million in the prior year
- Adjusted EBITDA Loss: $24.0 million, compared to a loss of $19.4 million in the prior year
- Cash and Cash Equivalents: $68.6 million as of July 31, 2026
- Total Liquidity: Approximately $320 million, including committed unused availability under the company’s term loan agreement
Dividend and Share Buyback
There were no dividends or share buybacks announced during this quarter, which is consistent with the company's focus on reinvesting in growth initiatives.
Guidance Update
Kestra has increased its fiscal year 2027 revenue guidance to $141 million, representing a growth of 48% compared to fiscal year 2026. This is an upward revision from the previous guidance of $137 million, indicating management's confidence in continued strong performance.
Forward-Looking Catalysts
Investors should watch for the following catalysts in the upcoming quarters:
- Continued expansion in the wearable cardioverter defibrillator (WCD) market, which has been a significant driver of revenue growth.
- The impact of new sales territories and a higher mix of in-network patients on revenue generation.
- Progress in the company's research and development initiatives, which could lead to new product offerings and enhancements.
- Monitoring of operating expenses to ensure that growth does not come at the expense of profitability.
In conclusion, Kestra Medical Technologies has delivered a strong quarter with impressive revenue growth and improved gross margins. While the increase in operating expenses and net losses is a concern, the overall trajectory of the company remains positive, and the increased guidance for the fiscal year suggests that management is optimistic about future performance. Investors should remain attentive to the company's execution on its growth strategy and the potential for further market expansion.
Note: All amounts are in thousands.
| Three Months Ended | July 31, 2026 | July 31, 2025 |
|---|---|---|
| Revenue | 30,971 | 19,371 |
| Cost of revenue | 13,473 | 10,520 |
| Gross profit | 17,498 | 8,851 |
| Operating expenses: | ||
| Research and development | 6,796 | 4,001 |
| Selling, general and administrative | 48,359 | 33,728 |
| Total operating expenses | 55,155 | 37,729 |
| Loss from operations | (37,657) | (28,878) |
| Other expense (income): | ||
| Interest expense | 1,929 | 1,912 |
| Interest income | (2,125) | (2,167) |
| Other expense (income), net | 272 | (2,830) |
| Loss on extinguishment of debt | 6,304 | — |
| Net loss before provision for income taxes | (44,037) | (25,793) |
| Provision for income taxes | 50 | 33 |
| Net loss attributable to common shareholders, basic and diluted | (44,087) | (25,826) |
| Net loss per share attributable to common shareholders, basic and diluted | $ (0.75) | $ (0.50) |
| Weighted-average common shares outstanding, basic and diluted | 58,566,467 | 51,304,599 |
| Other comprehensive loss: | ||
| Net loss | (44,087) | (25,826) |
| Unrealized loss on marketable securities | (253) | — |
| Comprehensive loss | (44,340) | (25,826) |
Note: All amounts are in thousands.
| July 31, 2026 | April 30, 2026 | |
|---|---|---|
| Cash and cash equivalents | 68,558 | 99,710 |
| Short-term investments | 130,353 | 96,724 |
| Accounts receivable, net | 15,406 | 14,542 |
| Disposable medical equipment supplies | 7,438 | 6,706 |
| Prepaid expenses and other current assets | 4,518 | 4,677 |
| Total current assets | 226,273 | 222,359 |
| Long-term investments | 45,791 | 65,767 |
| Right-of-use assets | 3,263 | 3,364 |
| Deposits | 1,842 | 1,761 |
| Restricted cash | 334 | 334 |
| Property and equipment, net | 63,656 | 59,090 |
| Other long-term assets | 6,196 | 5,790 |
| Total assets | 347,355 | 358,465 |
| Accounts payable | 25,961 | 27,295 |
| Accrued liabilities | 22,285 | 23,046 |
| Operating lease liabilities, current portion | 23 | 31 |
| Total current liabilities | 48,269 | 50,372 |
| Operating lease liabilities, net of current portion | 3,928 | 4,111 |
| Warrant liabilities | — | 1,369 |
| Other long-term liabilities | 306 | 306 |
| Long-term debt, net | 72,495 | 42,649 |
| Total liabilities | 124,998 | 98,807 |
| Common Shares, $1.00 par value; 100,000,000 shares authorized as of July 31, 2026 and April 30, 2026; 59,271,885 issued and outstanding as of July 31, 2026 and 58,383,924 shares issued and outstanding as of April 30, 2026 | 59,272 | 58,384 |
| Additional paid-in capital | 859,504 | 853,353 |
| Accumulated other comprehensive loss | (471) | (218) |
| Accumulated deficit | (695,948) | (651,861) |
| Total shareholders’ equity | 222,357 | 259,658 |
| Total liabilities and shareholders’ equity |
DisclaimerThe content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information. Related Articles Trending Stocks Intel Corporation (INTC) Q3 2026 Financial Results SummaryIntel Corporation (INTC) Q3 2026: Revenue Growth Amid Mixed Earnings — Cautiously Optimistic Intel Corporation reported its third-quarter 2026 financial results, revealing a notable increase in revenue but a decline in earnings per share (EPS) compared to the previous year. Specifically, revenue... QuoteReporter 4 minOct 30, 2026  Trending Stocks Alphabet (GOOG) GOOG Q3 Financial Results SummaryAlphabet Inc. (GOOGL) Q3 2026: Revenue Growth Accelerates, Cloud Soars — Strongly Positive Alphabet Inc. (GOOGL) reported impressive financial results for the third quarter of 2026, with consolidated revenues increasing by $25.2 billion or +25% year-over-year, reaching $127.6 billion. This marks... QuoteReporter 4 minOct 30, 2026  Trending Stocks Bristol Myers Squibb (BMY) Q3 2026 Financial Results SummaryBristol Myers Squibb (BMY) Q3 2026: Revenue Growth and Guidance Raise — Positive Outlook Bristol Myers Squibb (NYSE: BMY) reported its third-quarter financial results for 2026, showcasing a revenue increase of $0.9 billion or +7% year-over-year, reaching a total of $13.1 billion. This performance... QuoteReporter 4 minOct 30, 2026 |